Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg- Aims: To assess the long-term outcomes of GZ patients compared to IC in the absence of treatment.
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However, a substantial part of HBeAg-negative patients do not fit well into any of these 2 categories because ALT may be elevated in some patients with low HBV-DNA levels or vice versa. Since fluctuations of ALT, serum HBV-DNA or both occur frequently, the distinction of true IC from HBeAg-negative CHB may be difficult. These challenging situations have been described as "Grey Zone" (GZ). 2, 3 Little is known about the natural history of patients in the GZ since appropriate studies including large cohorts followed up for a long period of time are lacking. Consequently, whether these patients simply deserve long-lasting monitoring or need more active intervention remains uncertain. Furthermore, disagreement about the threshold that defines abnormal ALT values is also an issue; 40 U/L is traditionally considered as the UNL, but American (AASLD) guidelines recommend 19 U/L in women and 30 U/L in men. 2, 4 Moreover, the implication of viral genotype in the clinical outcomes of patients in the GZ has not been fully studied, particularly in non-Asiatic patients. 5, 6 Here, we report the observations made upon prolonged followup (FU) of untreated patients in the GZ in comparison with IC patients. We performed 2 separate analyses using the different ALT UNL thresholds recommended by the European (EASL) and American (AASLD) guidelines. 1, 2 In addition, we investigated the potential role of HBV genotypes in the clinical and virological events. In patients with available samples, HBsAg levels were determined at baseline and at the end of follow-up.
| PATIENTS AND METHODS

| Patient selection
All HBsAg-positive patients visited at the Liver Unit of the Hospital Clinic of Barcelona from January 1985 to January 2015 were reviewed. Only patients with negative HBeAg, positive anti-HBe, HBV-DNA level < 20 000 IU/mL and ALT below 80 U/L were included in this study. Other exclusion criteria included: cirrhosis, prior anti-viral therapy, liver disease other than HBV, organ transplantation, alcohol abuse (>40 grams in men and >20 grams in women) and immunosuppressive treatment prior to or during the study. To discard a possible underlying fatty liver disease, patients with ultrasonographic evidence of hepatic steatosis or body mass index (BMI) >25 kg/m 2 were excluded. The study was approved by the Ethical Committee of Hospital Cl ınic and was performed according to the Declaration of Helsinki.
| Patient classification at baseline
According to the highest HBV-DNA level and ALT activity observed in at least 4 determinations during the first 2 years of follow-up patients were classified into: (1) 
| Monitoring during follow-up
Patients were visited at least once a year or more often if clini- 
| Evaluation of liver fibrosis
Transient elastography (TE) was performed from 2006 onwards, and valid measurements were recorded. 8 Liver fibrosis was also estimated by: APRI (AST to platelets ratio), FIB-4 (fibrosis 4 index) and GPR (gamma-glutamyl transpeptidase to platelet ratio). Previously described cut-offs to discard moderate fibrosis (F ≥ 2) were APRI ≤ 0.5; FIB-4 ≤ 1.45; GPR ≤ 0.32 and TE ≤ 6 kPa. 15, 16 and the results were reported as negative, weakly positive or positive. 3 | RESULTS
| Baseline characteristics
In total, 287 untreated patients with HBeAg-negative chronic HBV infection, HBV-DNA ≤20 000 IU/mL and ALT ≤80 U/L were included ( Figure 1 ). HBeAg was already negative at the first visit in 215 patients, and 72 patients were included following documented spontaneous HBeAg seroconversion. Baseline characteristics of the study cohort are depicted in Table 1 .
According to the defined criteria, 137 patients (47.7%) belonged to the IC group and 150 patients (52.3%) to the GZ.
Among the latter, the distribution was: 60 (21%) GZ-1 (HBV- Table 1) .
Recent history of spontaneous HBeAg seroconversion was similar across groups, although the mean time elapsed since HBeAg seroconversion and inclusion in the study was longer among GZ-2 patients. By definition, ALT levels were significantly higher in GZ-1 and GZ-3 groups.
HBV genotype was identified in 185 (64.4%) patients. Genotyping was not possible in the remaining 102 (35.6%), either because serum was not available (n = 59) or for technical reasons (n = 43), mostly related to the low amount of HBV-DNA present in some serum samples (Table 1) . A and D were the most prevalent genotypes in Caucasian patients, genotype F in Latin-American, and genotypes B and C were exclusively seen in Chinese patients.
Importantly, HBV genotypes were similarly distributed among groups (Table 2) .
Non-invasive fibrosis tests (APRI, FIB-4 and GPR) excluded
advanced fibrosis in all groups at baseline (Table 1) .
| Biochemical and Virological changes during follow-up
Patients were followed up for a median of 8.2 (5-19) years, and the median follow-up duration was similar across groups (Table 3) .
ALT fluctuations were observed frequently overtime. Overall, about 30% of IC patients showed ALT elevations >40 U/L, although values >80 U/L occurred in only 6.6%. GZ patients presented a more dynamic biochemical behaviour, with up to 28.5% of patients reach-
ing ALT values >80 U/L. Nonetheless, at the end of the study, ALT were within normal values (<40 U/L) in 95% and 75% of IC and GZ patients respectively (Table 3 ).
The HBV-DNA profile of IC and GZ-1 patients was similar during follow-up. Elevations of HBV-DNA >20 000 IU/mL were exceptional, but fluctuations up to 20 000 IU/mL were relatively frequent (23%) and mostly transient. Indeed, at the end of followup, HBV-DNA remained <2000 IU/mL in about 90% of patients in these 2 groups. By contrast, more than 40% of GZ-2 and GZ-3 patients presented HBV-DNA fluctuations >20 000 IU/mL, although these levels persisted in only 26% of GZ-2 and in 11% of GZ-3 patients at last evaluation. Thus, virological remission (HBV-DNA levels <2000 IU/mL) was achieved in 30% and 64% of patients from GZ-2 and GZ-3 groups, respectively at the end of the study (Table 3) .
Fluctuations of HBV-DNA >20 000 IU/mL were more common in genotype B/C patients, but due to the small number of patients infected with these genotypes, the difference did not reach statistical significance (Table 2 ). (Table 4) . By multivariate analysis including only baseline variables, age and gender remained independently associated with HBsAg loss.
When including follow-up variables, the presence of HBV-DNA fluctuations >20 000 IU/mL remained as an independent negative predictor of HBsAg loss. When analysing patients with baseline HBV-DNA <2000 IU/mL (IC and GZ-1), HBV-DNA fluctuations >2000 IU/ mL during follow-up were also a negative predictor of HBsAg loss.
Transition to inactive carrier state Figure 2A ). By multivariate analysis only age >40 years was independently associated with transition into the IC state, while ALT fluctuations >80 U/mL and HBV-DNA fluctuations >20 000 IU/mL remained as negative predictors (Table 4) .
Development of HBeAg-negative chronic hepatitis B (HBeAgnegative CHB)
Progression to HBeAg-negative CHB occurred in only 18 patients (6.3%), all classified as GZ patients at baseline. The distribution of HBeAg-negative CHB was 8.3%, 14.8% and 13.8% among GZ-1/2/3 patients respectively (Figure 2A ). Liver fibrosis progression to F ≥ 2 was documented in 9 patients (4 GZ-1, 3 GZ-2 and 2 GZ-3). Nine additional patients (1 GZ-1, 5 GZ-2 and 3 GZ-3) presented HBV-DNA above 20 000 IU/mL with ALT >80 U/mL and were considered HBeAg-negative CHB, according to current guidelines. The overall cumulative probability of developing HBeAg-negative CHB at 2, 4 and 8 years of follow-up was 1%, 2% and 6% respectively but no independent factors were identified due to low number of cases.
Since therapeutic recommendations varied overtime and anti-viral drugs were not available during part of the study period, anti-viral therapy was administered to only 13 of patients. The median time for anti-viral treatment initiation was 6.3 years. HBsAg levels and serum HBV-DNA at the end of the follow-up (P = 0.573, P = 0.01). 
| Liver fibrosis and clinical events
| DISCUSSION
Distinction between inactive carrier and active HBeAg-negative chronic hepatitis B (HBeAg-negative CHB) states is a relevant issue due to the different outcomes: IC patients have a good prognosis, [17] [18] [19] whereas patients with HBeAg-negative CHB may progress to cirrhosis and its complications and benefit from anti-viral therapy. 20, 21 Serial monitoring of serum HBeAg, HBV-DNA and ALT levels has been used for classification of patients; the latter may be refined by quantification of serum HBsAg level, as suggested by recent studies. 22, 23 Nevertheless, some subjects fall into an indeterminate Grey area even after a complete assessment. Moreover, surveillance strategies in chronic HBV patients in the absence of treatment are mostly derived from Asiatic population and might not be universally applicable. To date, appropriate studies on the natural history of Caucasian patients in the GZ are not available.
In the current study, 137 (48%) IC and 150 (52%) patients classified as GZ were closely followed up for a long period to assess their virological and clinical outcomes. In accordance with data from our geographical area, most patients were infected with genotype A and D. 22, 23 Previously treated patients were not included in order to focus the analysis on the natural course of HBV infection. As the GZ is a rather heterogeneous condition that includes patients with different combinations of ALT and HBV-DNA patterns, patients were classified into 3 categories based on the presence of elevated ALT, elevated HBV-DNA or both. A relevant finding of this study is that the GZ is a relatively frequent form of presentation of chronic HBV
T A B L E 3 Biochemical and virological patterns during and at the end of follow-up according to baseline classification
Inactive carriers (n = 137) sented more marked HBV-DNA fluctuations with more than 40% of cases presenting levels >20 000 IU/mL. However, at the final evaluation most patients had normal ALT levels, and more than 40% of GZ-2 and GZ-3 patients presented low HBV-DNA levels (<2000 IU/ mL), suggesting that spontaneous inactivation of the disease can frequently occur among GZ patients over time. Indeed, 60 of GZ patients at baseline became IC at the end of follow-up. Importantly, during follow-up, only 6.3% of patients met treatment criteria according to current guidelines. of HBsAg was associated with older age (which possibly indicates a long-lasting infection) and lack of HBV-DNA peaks, but was unrelated to patient classification at baseline. Moreover, the absence of anti-viral therapy might contribute to a high HBsAg loss rate, particularly among patients classified as GZ. 25 A sub-analysis of patients with available HBV genotype suggests that patients infected with genotype B or C were more prone to develop HBeAg-negative CHB and had a lower rate of HBsAg loss. The latter finding is relevant, since it may explain some of the differences in outcomes found in this compared to Asian studies. [26] [27] [28] A more restrictive definition of ALT normal threshold, following AASLD guidelines, 2 showed, as expected, that a higher proportion of patients would have been classified as GZ or HBeAg-negative CHB.
The latter may have important implications for patient management, Quantification of serum HBsAg levels provides additional information concerning classification and prognosis of patients with chronic HBV infection and low viral replication. Indeed, either a single point or a dynamic assessment of HBsAg levels has been shown to be useful to differentiate true IC from patients with active chronic hepatitis B. [29] [30] [31] In agreement with these studies, we found that the median HBsAg levels were significantly lower in IC than in GZ patients, both at baseline and at the end of follow-up. Despite the relatively small number of patients, we also found a progressive increase of median HBsAg levels within the GZ categories, further Regarding fibrosis progression and clinical outcomes, a recent review including 331 patients with persistently normal ALT and HBV-DNA <20 000 IU/mL showed that liver necroinflammatory activity was minimal in 90% and liver fibrosis was absent or mild in 92%. 32 There is less information concerning liver histology in other GZ subpopulations, but available data indicate that most of those do not present significant liver disease. 33 In our study, surrogate markers of liver fibrosis, such as APRI, FIB-4 and GP ratio scores, strongly suggested absence of significant liver fibrosis at baseline, and interestingly, at the end of follow-up, these biomarkers showed a decrease compared to baseline. A significant proportion of patients underwent TE at the end of follow-up showing low fibrosis scores, in good concordance with non-invasive biomarkers. Indeed, TE cut-off of 6 kPa could exclude significant fibrosis in more than 90% of cases. 34 Based on these findings, fibrosis progression was reasonably excluded in most of the patients at the end of the study. Of note, no patient fulfilled criteria of cirrhosis, whereas only 1 genotype C patient developed HCC.
Our study has some limitations. First, its retrospective nature is an inherent limitation since we cannot exclude the presence of selection bias at entry or inaccuracies during follow-up. However, the fact that only 2 liver specialists followed these patients during the study period reduces, at least in part, these potential limitations.
Second, since different methods were used overtime to assess serum HBV-DNA, the classification of patients at baseline may not be fully Genotype B/C n = 12
Genotype F n = 12
Genotype E/H n = 7
HBsAg negative Inactive carrier Grey Zone HBeAg neg. CHB n = 17 n = 8 n = 47 n = 19 n = 5 n = 34 n = 17 n = 7 n = 6 n = 2 n = 4 n = 6 n = 6 n = 4 n = 3 Proportion of patients in each group (%) cccDNA, 24, 35 could not be performed. However, the optimal cut-off and the utility of these markers in this setting is still matter of debate. 36 Finally, histological assessment was available only in some patients. However, guidelines recommend non-invasive markers of fibrosis as the first-line modality for disease evaluation and emphasise that these are more accurate at excluding than at confirming advanced fibrosis or cirrhosis. 1, 9 In our study, the stability of noninvasive serological markers of fibrosis overtime and the concordance with TE reasonably discarded the presence of fibrosis progression in 95% of the patients.
In summary, our results show that Caucasian GZ patients present excellent outcomes after a long-term follow-up, which is in line with a recent study in HBeAg-negative patients with low replication. 
